CytRx Receives Recommendation for Aldoxorubicin; Celgene's Apremilast Achieves Statistical Significant for Primary, Major Secondary Endpoints Print E-mail
By Staff and Wire Reports   
Monday, 06 May 2013 19:32
Below is a look at some of the headlines for companies that made news in the healthcare sector on May 6, 2013.

CytRx Corporation (NASDAQ: CYTR)
, a biopharmaceutical research and development company specializing in oncology, announced the independent Data Safety Monitoring Committee (DSMC) overseeing the Company's international Phase 2b clinical trial with aldoxorubicin as a first-line treatment for patients with late-stage metastatic soft tissue sarcoma has recommended conducting the clinical trial through completion. This Phase 2b trial allows for a head-to-head clinical comparison of the commonly used chemotherapeutic agent doxorubicin with aldoxorubicin, CytRx's tumor-targeting doxorubicin conjugate. Doxorubicin is dose-limited at a level below its maximum anti-tumor capabilities due to toxicity, including cardiotoxicity. Data from the Phase 2b trial is expected in the second half of 2013.

“The recommendation to complete the Phase 2b trial indicates that the DSMC found no significant safety issues with aldoxorubicin, even though the dose of aldoxorubicin administered in this trial delivers doxorubicin at three-and-a-half times its standard dose,” said CytRx CEO Steven A. Kriegsman. “The DSMC was not charged with evaluating efficacy at this point in the study. Aldoxorubicin combines doxorubicin with our proprietary linker technology. This platform technology includes a single molecule that, when attached to a chemotherapeutic agent, allows for concentration of the agent at the tumor site, thus allowing for greater drug infusion into the tumor. We believe that safely concentrating more drug at the tumor site could improve the drug's effectiveness.

“Aldoxorubicin is the first drug we are evaluating in the clinic based on the linker technology. Doxorubicin was selected for evaluation as it is well-known and has been used by the medical community for decades; however the linker has broad potential utility with proven affinity to couple with multiple chemotherapeutic agents including paclitaxel, docetaxel, cisplatin, irinotecan and methotrexate. Each of these agents may be incorporated into our future clinical development plans,” he added.

The Phase 2b trial is enrolling a total of 105 patients with metastatic, locally advanced or unresectable soft tissue sarcomas who have not been previously treated with any chemotherapy and are ineligible for surgery. Patients in the trial are randomized into two groups, with twice as many receiving aldoxorubicin as doxorubicin. The trial's primary objective is to compare progression-free survival between each group. Secondary endpoints include evaluating tumor response and overall patient survival, and assessing the safety of aldoxorubicin compared with doxorubicin in this patient population through a number of indicators, including the frequency and severity of adverse events. Patients are being enrolled in clinical sites in the U.S., Hungary, Romania, Russia, Ukraine, India and Australia.

CytRx holds exclusive worldwide rights to aldoxorubicin, as well as option rights to the protein-binding platform technology that serves as the linker with doxorubicin.


======


Celgene International Sàrl, a subsidiary of Celgene Corporation (NASDAQ: CELG) announced statistical significance was achieved for the primary endpoint of ACR 20 at week 16 for patients receiving apremilast 20 mg and 30 mg BID monotherapy in PALACE 4. PALACE 4 is the fourth randomized, placebo-controlled study evaluating the Company's novel, oral small-molecule inhibitor of phosphodiesterase 4 (PDE4) in patients with psoriatic arthritis. This is the first Company-sponsored trial studying patients who had not previously received an oral disease-modifying antirheumatic drug (DMARD).

“Despite recent advances in the treatment of psoriatic arthritis, there remains a significant need for more oral DMARD treatment options for DMARD-naïve patients,” said Randall Stevens, VP of Clinical Research and Development for Inflammation & Immunology. “PALACE-4 is now the fourth major randomized apremilast Phase III study to provide promising results for patients with psoriatic arthritis.”

Patients on apremilast also achieved a statistically significant benefit over placebo in key secondary endpoints, as demonstrated in various measures of physical function and signs and symptoms, including enthesitis.

No new safety and tolerability signals identified, with fewer AEs and SAEs reported than in PALACE 1, 2&3. Importantly, in PALACE 4, no systemic opportunistic infections (including TB) or lymphoma were observed through week 24, and there was no increase in risk of cardiovascular events. The most common AEs in PALACE 4 (≥5%) were nausea, diarrhea and headache.

The PALACE 4 study is ongoing and the study extension remains blinded until all patients complete week 52. Full data from this phase III study will be submitted for presentation at appropriate medical meetings.

Results from PALACE 1, one of three registrational randomized, placebo-controlled phase III studies of apremilast in PsA were released at ACR in November 2012. Top-line positive results from the two additional registrational studies of apremilast in PsA (PALACE 2 and PALACE 3) were released in September 2012. Twenty-four-week topline results of PALACE 3 and 52-week results from PALACE 1 will be presented at EULAR in June 2013. Taken together, the PALACE program is the most comprehensive set of psoriatic arthritis studies to date intended for regulatory submission. Results from the PSA-001 phase II study of apremilast in psoriatic arthritis were recently published online in the journal Arthritis & Rheumatism

In addition, positive results from two large, pivotal global studies of apremilast in more than 1,200 patients with moderate-to-severe plaque psoriasis (ESTEEM 1 and 2) were released in January 2013, with full results from ESTEEM 1 presented at AAD in March. Results from PSOR-005, a phase IIb dose-range study of apremilast in psoriasis, were recently published in The Lancet

A randomized, placebo-controlled phase III study (POSTURE) of apremilast in ankylosing spondylitis (AS) began enrolling patients in April 2012. AS, a debilitating disease, which may cause fusion of the spine, arthritis, inflammation of the eye and damage to the heart and affects approximately 2.5 million people in the U.S. and Europe. The trial will randomize approximately 450 patients to receive 20mg or 30mg apremilast, or placebo BID. The primary endpoint is the proportion of patients achieving an ASAS 20 score at week 16.

These results are from an investigational phase III study. Apremilast is not approved for the treatment of psoriatic arthritis.

The NDA/NDS submissions, based on the combined data from PALACE 1, 2 &3 for PsA, were submitted to health authorities in the US and Canada in Q12013 and Q2 2013 respectively. The Company previously announced it expects to file a separate NDA in the US for psoriasis and a combined PsA/psoriasis MAA submission in Europe in the second half of 2013.


Also Monday:



Advanced Cell Technology, Inc. (OTCBB: ACTC)
, a leader in the field of regenerative medicine, announced today that it will release its first quarter financial results for the period ended March 31, 2013 after the market closes and hold an earnings call on Thursday, May 9th, 2013 at 4:30 p.m. EDT during which it will discuss these results and provide a corporate update.

Anavex Life Sciences Corp. ("Anavex") (OTCQB: AVXL)
today announced that it has been invited to submit a full grant application to the Alzheimer's Drug Discovery Foundation ("ADDF") for a Phase 2a trial of ANAVEX 2-73.

CEL-SCI Corporation (NYSE MKT: CVM)
today announced results from a recently completed efficacy study in a second animal model of rheumatoid arthritis (RA) using the LEAPS technology (LEAPS), which demonstrates that LEAPS has the potential for use as a therapeutic vaccine to treat different types of RA, each of which possesses different disease characteristics.

Array BioPharma Inc. (NASDAQ: ARRY)
today reported results for the third quarter of its fiscal year ending June 30, 2013.

Digirad Corporation (NASDAQ: DRAD)
today reported revenue of $11.5 million for the first quarter and an ending cash, cash equivalents and available-for-sale securities balance of $25.8 million.

Guided Therapeutics, Inc. (OTCBB: GTHP) (OTCQB: GTHP)
, developer of a rapid and painless testing platform that uses biophotonics for the early detection of disease, today announced that it is scheduled to report financial results for its first quarter ended March 31, 2013 on Tuesday, May 14, 2013, after the market closes.

Hansen Medical, Inc. (NASDAQ: HNSN)
, a global leader in intravascular robotics, today announced that it will be exhibiting its Magellan™ Robotic System at the 8th Annual European Symposium of Vascular Biomaterials (ESVB) from Friday, May 10th to Monday, May 13th at the Strasbourg Hilton in Strasbourg, France.

Sunday, May 12, is Mother’s Day, and Health Net, Inc. (NYSE: HNT) is marking this global commemoration by helping to increase awareness regarding the importance of preconception health for women planning to become mothers.

Insulet Corporation (NASDAQ: PODD)
, the leader in tubeless insulin pump technology with its OmniPod® Insulin Management System, today announced financial results for the first quarter ended March 31, 2013.

La Jolla Pharmaceutical Company (OTCBB: LJPC)
("La Jolla" and "Company"), a leader in the development of therapeutics targeting galectin proteins, announced today that it has treated the last patient in the Phase 1 (Part A) portion of the Phase 1/2 clinical trial of GCS-100 in patients with chronic kidney disease ("CKD").

Medidata Solutions (NASDAQ: MDSO)
, the leading global provider of cloud-based solutions for the life sciences industry, today announced that Tarek Sherif, chief executive officer, and Cory Douglas, chief financial officer, will present at the Jefferies 2013 Global Technology, Media & Telecom Conference on May 9, 2013, at 9.00 a.m. ET in New York City.

MMRGlobal, Inc. (OTCQB: MMRF)
("MMR"), a leading provider of Personal Health Records (PHRs) MyEsafeDepositBox storage solutions and MMRPro document management and imaging systems for healthcare professionals, is featured in an updated valuation report following the issuance by the Japan Patent Office of Patent No. 5191895 entitled a "Method and System for Providing Online Medical Records."

Neogen Corporation (Nasdaq: NEOG)
announced today the development of a new genomic test that offers the beef cattle industry an unprecedented level of information on the genetic potential of individual animals.

NuVasive, Inc. (NASDAQ: NUVA)
, a medical device company focused on developing minimally disruptive surgical products and procedures for the spine, announced today the acquisition of ANC, LLC, a spine implant manufacturer based in Dayton, Ohio.

Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY)
announced today that its 2013 Annual and Special Meeting of Shareholders will be held on Thursday, May 9th, 2013 at 3:00 p.m. MT at the Hotel Le Germain Calgary, 899 Centre Street SW Calgary, Alberta.

PharmAthene, Inc. (NYSE MKT: PIP)
, a biodefense company developing medical countermeasures against biological and chemical threats, today announced that its financial and operating results for the first quarter of 2013 will be released on Wednesday, May 8, 2013.

ProPhase Labs, Inc. (NASDAQ: PRPH)
(www.ProPhaseLabs.com) today reported a net sales increase of 25.3% to $7.5 million for the three months ended March 31, 2013 as compared to net sales of $6.0 million for the three months ended March 31, 2012.

Quidel Corporation (NASDAQ: QDEL)
, a provider of rapid diagnostic testing solutions, cell-based virology assays and molecular diagnostic systems, announced today that it completed the acquisition of BioHelix Corporation (BioHelix).

Rockwell Medical, Inc. (NASDAQ: RMTI)
, a fully-integrated biopharmaceutical company offering innovative products and services targeting end-stage renal disease (ESRD), chronic kidney disease (CKD), and iron deficiency anemia, announced today that clinical data for its late-stage investigational drug Soluble Ferric Pyrophosphate (SFP) has been accepted for presentation at the 50th European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress Istanbul, Turkey, May 18-21, 2013.

Senesco Technologies, Inc. (OTC QB: SNTI)
reported today that the Data Review Committee (DRC) for its SNS01-T trial in multiple myeloma and non-Hodgkins B-cell lymphoma approved initiating cohort 3 and escalating the SNS01-T dose level four-fold to 0.2 mg/Kg.

Teva Women’s Health, a U.S.-based subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), today announced new data for the oral contraceptives (OC) QuartetteTM (levonorgestrel/ethinyl estradiol and ethinyl estradiol) tablets and an investigational 28-day OC regimen (150 mcg desogestrel (DSG)/20 mcg ethinyl estradiol (EE) for 21 days, followed by 7 days of 10 mcg EE) will be featured at the 61st Annual Meeting of the American Congress of Obstetricians and Gynecologists (ACOG).

Titan Medical Inc. (TSX VENTURE:TMD) (OTCQX:TITXF)
today announces that it has completed prototyping of its 3D HD chip-on-tip camera system to be used in its Single Incision surgery system.



"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter